Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis-Reference-Cited by-同舟云学术

Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis

Published:2005-01 Issue:1 Volume:45 Page:26-34
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Karkouti Keyvan,Beattie W. Scott,Wijeysundera D.N.,Yau Terrence M.,McCluskey Stuart A.,Ghannam Mohammed,Sutton David,van Rensburg Adriaan,Karski Jacek

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1537-2995.2005.04216.x/fullpdf

Reference26 articles.

1. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery

2. An Effective Treatment of Severe Intractable Bleeding After Valve Repair by One Single Dose of Activated Recombinant Factor VII

3. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device

4. Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of public workforce diversity and the administrative ecosystem in advancing digital public service innovation;Public Management Review;2024-01-16

2. Recombinant Activated Factor VII (rFVIIa) for Bleeding After Thoracic Aortic Surgery: A Scoping Review of Current Literature;Journal of Cardiothoracic and Vascular Anesthesia;2024-01

3. Trends in the Use of Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Heart Transplant Patients in Virginia;Journal of Cardiothoracic and Vascular Anesthesia;2023-10

4. Off-label Use of Recombinant Activated Factor VII for Cardiac Surgical Bleeding;Anesthesiology;2023-05-08

5. Factor eight inhibitor bypassing activity for refractory bleeding in coronary artery bypass grafting: A propensity‐matched analysis;Research and Practice in Thrombosis and Haemostasis;2022-11